Prolonged diabetic ketoacidosis associated with canagliflozin
نویسندگان
چکیده
منابع مشابه
Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve glycemic control by a reversible inhibition of the sodium-glucose cotransporters in the renal proximal tubules resulting in increased urinary glucose. This unique mechanism, independent of insulin secretion and beta cell function, has made this class of medication desirable in patients with type 2 diabetes. However in May 2015, the US Fo...
متن کاملCanagliflozin-Induced Diabetic Ketoacidosis
INTRODUCTION Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are relatively new antihyperglycemic agents that lower renal glucose reabsorption. They are used as adjunctive therapy to standard diabetes treatment. CASE REPORT We present the case of a 62-year-old woman with a past medical history of type 2 diabetes mellitus and sudden-onset diabetic ketoacidosis (DKA). Use of canagliflozin, ...
متن کاملEuglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin
Diabetic ketoacidosis is characterized by hyperglycemia, anion-gap acidosis, and increased plasma ketones. After the resolution of hyperglycemia, persistent diuresis is rare. We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persist...
متن کاملSevere Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.
Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for the treatment of type 2 diabetes mellitus (DM). Though not FDA approved yet, its use in type 1 DM has been justified by the fact that its mechanism of action is independent of insulin secretion or action. However, some serious side effects, including severe anion gap m...
متن کاملAntipsychotic medicines associated with diabetic ketoacidosis
All patients should be screened for hepatitis B before starting treatment with direct-acting antivirals for hepatitis C. Patients co-infected with hepatitis B and C who are treated with directacting antivirals should be monitored and treated according to current clinical guidelines. The recommendations from the EMA are available here: Direct-acting antivirals for hepatitis C: EMA confirms r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Endocrinology, Diabetes & Metabolism Case Reports
سال: 2018
ISSN: 2052-0573
DOI: 10.1530/edm-17-0177